The objective of this study was to characterize the HCV cascade of care in a bridge clinic setting and identify barriers to HCV treatment in this population. This study demonstrated that several challenges and barriers exist to engage patients in HCV care in a bridge clinic model, and more strategies should be identified to engage patients and link them to care.

This study evaluated the rate and reasons for Primary Medication Nonadherence (PMN) to specialty oral oncology medications in Health System Specialty Pharmacies (HSSP). Multisite retrospective cohort study across 7 HSSP sites. Most patients (89%) prescribed oral oncology treatment at HSSP initiated therapy. Primary medication nonadherence was mostly due to patient decision.

The goal of this study was to explore healthcare providers’ experiences with specialty medications distributed via Limited Distribution Networks (LDN) that do not include IHSSPs. Participants reported barriers to navigating LDNs that can interfere with clinic workflow and patient care. IHSSPs may reduce clinic burden by helping patients access, afford, and remain on therapy.

This multisite, prospective, cohort study of patients with MS evaluated patient-reported outcomes, pharmacists' actions, and DMT adherence/persistence. Patients reported low rates of impacted productivity, hospitalization, and relapse due to MS. Pharmacists commonly provided medication education and actions to ensure DMT safety and adherence. Patients had a high rate of adherence (median PDC 88%) and persistence (86% at 12 months). Findings support positive outcomes for HSSP patients.

This study assess the impact of pharmacist-led tailored monitoring for patients initiating encorafenib and binimetinib combination therapy. A retrospective study showed that in the first 90 days of treatment 44% of patients required at least 1 treatment interruption, 39% required at least 1 dose reduction, 11% discontinued therapy. A prospective study reporting the impact of implementing a pharmacist-led targeted monitoring program is forthcoming.

This study assess the impact of pharmacist-led tailored monitoring for patients initiating PARP inhibitor therapy. A retrospective study showed that all patients were able to access medicaiton through the pharmacist-led insurance approval process and 64% of patients required a treatment modification in the first 90 days of therapy. A prospective study reporting the impact of implementing a pharmacist-led targeted monitoring program is forthcoming.